Last reviewed · How we verify
ODM-108 Part I
ODM-108 Part I mechanism of action is not publicly disclosed; Phase 1 development was terminated.
ODM-108 Part I is an early-stage investigational compound developed by Orion Corporation (Orion Pharma) that was discontinued after Phase 1 clinical evaluation. The drug is a small molecule with a molecular weight of 369.39 Da, though its precise mechanism of action and molecular target remain undisclosed in available literature. A single Phase 1 trial enrolling 85 healthy male volunteers was terminated, assessing safety, tolerability, pharmacokinetic, and pharmacodynamic effects. The compound did not advance to Phase 2 development, indicating either safety/tolerability concerns or strategic portfolio decisions by Orion. No approved indications, commercial revenue, or regulatory approvals exist. This profile represents a discontinued early-stage asset with limited clinical data and no commercial significance.
At a glance
| Generic name | ODM-108 Part I |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | Small molecule (investigational) |
| Target | Not disclosed |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
ODM-108 Part I is an investigational small molecule compound developed by Orion Corporation. The specific molecular target, binding mechanism, and pharmacological pathway have not been disclosed in publicly available sources. The compound underwent a single Phase 1 clinical trial in healthy volunteers to evaluate basic safety, tolerability, and pharmacokinetic properties before development was discontinued. Without published preclinical or clinical data, the precise mechanism of action cannot be determined from available sources.
Approved indications
Pipeline indications
- Indication under Phase 1 evaluation (not specified) — Phase 1
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ODM-108 Part I CI brief — competitive landscape report
- ODM-108 Part I updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI